Good
Partially Aligned
Patient Risk:
Moderate
Summary
Most pharmacologic and adverse-effect statements are consistent with the provided label excerpts (mechanism, anticholinergic effects, CNS/CV adverse effects). However, several effectiveness/timing statements and population/condition-use assertions are not explicitly supported by the provided excerpts and may be overly specific relative to what’s shown.
Category Scores
Accurate Statements
Dicyclomine is an anticholinergic and antispasmodic medication.
12.1 Mechanism of Action: anticholinergic (antimuscarinic) effect and direct effect upon smooth muscle; 12.2 notes drowsiness and other muscarinic/CV effects.
Dicyclomine is used to relieve cramps and spasms of the stomach, intestines, and bladder.
1 INDICATIONS AND USAGE: treatment of functional bowel/irritable bowel syndrome; 12.1: relieves smooth muscle spasm of the gastrointestinal tract. (Label excerpts provided do not support bladder/spasm relief.)
Dicyclomine functions by blocking the action of acetylcholine, a neurotransmitter that signals muscles to contract.
12.1 Mechanism of Action: anticholinergic (antimuscarinic) effect (supports anticholinergic blocking of muscarinic signaling via acetylcholine pathway as described in label context).
By inhibiting acetylcholine, dicyclomine relaxes smooth muscles of the gastrointestinal and urinary tracts.
12.1 Mechanism of Action: relieves smooth muscle spasm of the gastrointestinal tract via anticholinergic and direct smooth-muscle effects. (Urinary tract relaxation is not supported in the provided excerpts.)
Relaxation of smooth muscles by dicyclomine reduces spasms and pain.
12.1 Mechanism of Action: relieves smooth muscle spasm of the gastrointestinal tract. Label excerpt does not explicitly mention “pain,” but spasm relief is directly supported.
Common side effects of dicyclomine can include dry mouth, blurred vision, dizziness, drowsiness, and constipation.
5 WARNINGS AND PRECAUTIONS: may produce drowsiness, dizziness, blurred vision (5.3). 6.2 postmarketing examples include dry mouth and constipation (among others).
Less common but more serious side effects of dicyclomine may involve difficulty urinating, rapid heart rate, confusion, and severe allergic reactions.
6 ADVERSE REACTIONS: most serious adverse reactions include cardiovascular and CNS symptoms; 5.2 includes tachyarrhythmia/accelerate heart rate; 6.2 includes palpitations/tachyarrhythmias and delirium/psychosis symptoms. (Difficulty urinating and severe allergic reactions are not explicitly shown in the provided excerpts.)
Unsupported Statements
Dicyclomine is used to relieve cramps and spasms of the stomach, intestines, and bladder.
Provided label excerpt supports gastrointestinal tract spasm (12.1) and IBS/functonal bowel (1), but does not mention bladder/urinary tract treatment.
By inhibiting acetylcholine, dicyclomine relaxes smooth muscles of the gastrointestinal and urinary tracts.
Provided label excerpt supports gastrointestinal tract smooth muscle spasm relief (12.1); urinary tract relaxation is not supported by the excerpts given.
Dicyclomine is primarily prescribed to alleviate symptoms associated with irritable bowel syndrome (IBS), such as abdominal pain, cramping, and spasms.
Label excerpt states indication for functional bowel/IBS (1) but provided excerpts do not explicitly list “abdominal pain” as a symptom phrase or state “primarily prescribed.”
Dicyclomine may be used to manage spasms in other gastrointestinal conditions.
Provided label excerpt indicates functional bowel/IBS only (1) and does not support additional GI conditions beyond that.
Patients with glaucoma, myasthenia gravis, or certain heart conditions should use dicyclomine with caution or avoid it altogether.
Glaucoma and myasthenia gravis are contraindications per provided excerpts (4), not merely “use with caution.” Heart conditions are discussed as caution areas (5.2), but the combined statement is not fully supported as phrased.
The onset of action for dicyclomine can vary.
No onset-of-action statement is present in the provided excerpts.
Many individuals experience relief from symptoms within a few hours of taking dicyclomine.
No timing/percentage claim about symptom relief is present in the provided excerpts.
Dicyclomine effectiveness is often observed in reducing the frequency and intensity of abdominal cramps.
Provided clinical study excerpt reports favorable response rate vs placebo (14) but does not specify frequency/intensity of abdominal cramps.
Long-term use of dicyclomine may be associated with persistent side effects like chronic dry mouth or constipation.
Provided excerpts discuss adverse effects generally and some postmarketing reactions, but do not make a long-term/persistence association statement.
Less common but more serious side effects ... may involve difficulty urinating, rapid heart rate, confusion, and severe allergic reactions.
Tachyarrhythmias/rapid heart rate and confusion/delirium are supported broadly by provided excerpts (5.2, 6.2). Difficulty urinating and severe allergic reactions are not explicitly evidenced in the provided excerpts.
Contradictions
Low
AI Statement
Patients with glaucoma, myasthenia gravis, or certain heart conditions should use dicyclomine with caution or avoid it altogether.
Label Reference
4 CONTRAINDICATIONS: glaucoma; myasthenia gravis (contraindicated). 5.2 covers caution for tachyarrhythmia/cardiovascular conditions, but the statement implies caution for glaucoma and/or myasthenia gravis rather than contraindication.
Important Omissions
No dosing-related content is provided by the AI claims, despite dosage guidance being a key label component (e.g., initial 20 mg QID, titration after 1 week, discontinue if not effective within 2 weeks, max/limits).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Primary safety-relevant claims are mostly consistent (anticholinergic effects; CNS/CV adverse reaction types). However, the glaucoma/myasthenia gravis statement is phrased as “caution or avoid,” which can understate that both are contraindications in the provided label excerpts. Several other claims are unsupported/overly specific (onset, timing of relief, urinary-bladder use, long-term persistence), which could mislead expectations or use scope.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Several statements extend beyond the provided label excerpts (bladder/urinary tract indications; additional GI conditions; onset/timing of symptom relief; long-term persistence; specific adverse effects like difficulty urinating/severe allergic reactions not shown). Additionally, glaucoma and myasthenia gravis are contraindications but were framed as caution/avoid.
Suggested Improvement
Restrict indication/mechanism claims to functional bowel/IBS and gastrointestinal smooth muscle spasm as supported (1, 12.1). Rephrase glaucoma and myasthenia gravis to reflect contraindications (4). Remove or generalize timing/onset and long-term persistence claims unless directly supported by the provided label excerpts.